Farhad Ravandi-Kashani

134PUBLICATIONS

322CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursGene and molecular therapyAutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (134)

Sort by Publication Date:

|Jun 27, 2026

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Jun 22, 2026

Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.

|Jun 15, 2026

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

|Jun 11, 2026

All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE).

|May 25, 2026

Post-transplant oral decitabine and cedazuridine maintenance in high-risk acute myeloid leukemia or myelodysplastic syndrome.

|May 17, 2026

Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALL.

Pageof 23

Frequent Collaborators

95 joint publications

Tapan M Kadia

84 joint publications

Nicholas Short

82 joint publications

Navel G Daver

82 joint publications

Hagop M Kantarjian

81 joint publications

Courtney DiNardo

77 joint publications

Elias Jabbour

70 joint publications

Gautam Borthakur

70 joint publications

Guillermo Garcia-Manero

54 joint publications

Koji Sasaki

48 joint publications

Ghayas Issa

Frequent Collaborators

95 joint publications

Tapan M Kadia

84 joint publications

Nicholas Short

82 joint publications

Navel G Daver

82 joint publications

Hagop M Kantarjian